--The New England Journal of Medicine published favorable clinical trial data about Johnson & Johnson's potential Covid-19 vaccine, including data about safety and immune response, CNBC reported.

-- Dr. Paul Stoffels, the company's chief scientific officer, told CNBC that the results give the company confidence about its vaccine.

Full story: https://www.cnbc.com/2021/01/13/covid-vaccine-johnson-johnson-one-shot-safe-generates-immune-response.html?__source=newsletter%7Cbreakingnews

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

January 13, 2021 17:35 ET (22:35 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024 Plus de graphiques de la Bourse Johnson and Johnson
Johnson and Johnson (NYSE:JNJ)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024 Plus de graphiques de la Bourse Johnson and Johnson